KROS Q3 2024 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$388,000+4750.0% YoY

Gross Profit

$74,00019.1% margin

Operating Income

-$59M-15117.8% margin

Net Income

-$53M-13648.5% margin

EPS (Diluted)

$-1.47

QoQ Revenue Growth

+948.6%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$579M

Total Liabilities

$46M

Stockholders' Equity

$533M

Cash & Equivalents

$531M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$388,000	$8,000	+4750.0%
Gross Profit	$74,000	-$543,000	+113.6%
Operating Income	-$59M	-$43M	-35.5%
Net Income	-$53M	-$39M	-34.3%

Revenue Segments

Service

$400,000100%